Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Year: 2019
Type: conference-abstract
Source: Cancer Research
Institutions: Johns Hopkins University, Royal United Hospital, Asan Medical Center, Seoul National University Hospital, University of Ulsan, NYU Langone Health, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Vall d'Hebron Institute of Oncology, NYU Langone’s Laura and Isaac Perlmutter Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2923848698